1. Introduction
Multiple Sclerosis (MS) is a chronic, progressive, immune mediated central nervous system (CNS) disorder that affects both adults and children. MS is characterized by the formation of multiple lesions along the nerve fibers in the brain, spinal cord and optic nerves (Bradl and Lassmann, 2009; Bruck, 2005; Bruck and Stadelmann, 2005; Chitnis et al., 2009; Hafler, 2004; Holland, 2009; Mah and Thannhauser, 2010; Pohl et al., 2007). The precise triggers of autoreactive T cell development remain to be fully understood, however, it is clear that myelin antigens are the major target (Grau-Lopez et al., 2009). T cell activation results in cytokine release and recruitment of other immune cells that results in tissue damage not only to the myelin sheath but, over time and with repeated attacks, to the underlying axons as well. Demyelination and axonal damage impairs or interrupts nerve transmission, giving rise to clinical signs and symptoms.
Clinically, neurological symptoms in patients with MS vary from mild to severe and typically include one or more of the following: sensory symptoms (numbness, tingling, other abnormal sensations, visual disturbances, dizziness), motor symptoms (weakness, difficulty walking, tremor, bowel/bladder problems, poor coordination, and stiffness), and other symptoms such as heat sensitivity, fatigue, emotional changes, cognitive changes and sexual symptoms (Bronner et al., 2010). While some persons have a limited number of “attacks” or “relapses” and remain fairly healthy for decades, others may deteriorate rapidly from the time of diagnosis, with poor quality of life and shortened lifespan. There is no way of knowing at the clinical onset what course the disease will take (Andersen, 2010; Bradl and Lassmann, 2009; Bruck, 2005).
In this chapter how the autoimmune process is triggered as well as current clinical options to try and reduce disease symptoms are addressed. While the induction of long-term durable antigen-specific T cell tolerance is the desired treatment option, such a therapy remains to be clinically developed. Instead, once a diagnosis of MS is made, immune based treatment is generally begun, with numerous therapies aimed primarily at inactivating T cells and other immune functions.
2. Multiple Sclerosis triggers and animal models
The ability for the immune system to differentiate between self and non-self is critical for host preservation. Deficits in self-non-self discrimination can result in opportunistic infections or immunological over-reactivity resulting in immunopathology and autoimmunity. It is therefore, not surprisingthat multiple genetic factors that influence the sensitivity of the immune system are known to trigger autoimmune mediated diseases. However it is hypothesized that clinical symptom development may only manifest after exposure to certain environmental factors, including viral infection. The interplay of genetics and the environment in regards to the development of MS, and other autoimmune diseases, has not been completely elucidated. No matter what the potential switch that causes MS initiation the activation, proliferation and effector functions of auto-reactive CD4+ T cells appears to be critical for disease development and progression (Goverman, 2009; Miller and Eagar, 2001; Miller et al., 2001).
i. Predisposing genetic factors
The significantly higher concordance rates of MS in monozygotic twins compared to dizygotic twins (Hansen et al., 2005; Islam et al., 2006; Willer et al., 2003), the 2-fold increased risk of disease development in siblings of affected individuals (Ebers et al., 2004) as well as the observed increased susceptibility in offspring from two affected parents, compared to those with only one affected parent (Ebers et al., 2000; Robertson et al., 1997) all point to a strong genetic component in the pathogenesis of MS. However, like many other complex autoimmune diseases, MS is not transferred from parent to offspring via classic Mendelian genetics and the disease trait involves a large number of genes (Hoffjan and Akkad, 2010). Until recently, most gene variations associated with increased or decreased susceptibility were thought to be within the human leukocyte antigen (HLA) loci (Ramagopalan et al., 2009). However, recent studies have also identified risk-conferring alleles within several non-HLA genes (Nischwitz et al., 2011). Importantly, most of these genes are known to play important roles in T cell activation and function, which further supports the concept that a dysfunctional immune process is involved in the initiation and progression of MS (Nischwitz et al., 2011).
ii. HLA genes
Allelic variations within the major histocompatibility complex (MHC) exert the greatest individual effect on the risk of MS (Ramagopalan et al., 2009). Initial studies published in 1972 identified the HLA Class I antigens
Other HLA-DR2 alleles that confer susceptibility in some populations include
iii. Non-HLA genes
Early gene linkage studies failed to validate associations between non-HLA genes and the development of MS, potentially due to the small individual contribution of each gene to disease (Nischwitz et al., 2011). However, in recent years, several GWAS have identified polymorphisms within a number of non-HLA genes that play an important role in the development of MS (Pravica et al., 2012). These include genes that are involved in cytokine pathways, such as those encoding the IL-2, IL-7, IL-12 and TNF receptors, which are important for T cell development, homeostasis, proliferation and differentiation (2009; Baranzini et al., 2009; Sawcer
Also, variations within genes coding for co-stimulatory molecules, such as CD40, CD58, CD80 and CD86, which promote the activation of T cells, were also implicated in susceptibility to MS (2009; Baranzini et al., 2009; Sawcer
Variations within other genes that can affect T cell functioning, including CD6, CLEC16A, and the vitamin D alpha hydroxylase gene CYP27B1 are also implicated in the pathogenesis of MS (2009; Baranzini et al., 2009; Sawcer
There is clearly further research to be performed to better understand the role of genetics and MS development. However the data clearly show that genes associated with T cell activation and other immune functions certainly highlight the importance of targeting immune factors when treating disease.
3. Environmental factors
Although it is clear that genetics play a key role in determining susceptibility to MS, concordance rates between monozygotic twins (
i. Infectious factors
For many years, underlying infections have been implicated in the induction of the autoreactive CD4+ T cell response that leads to MS (Kakalacheva and Lunemann, 2011). Roles for several pathogens, including Epstein Barr Virus (EBV), Human Herpes Virus-6 (HHV-6) and Varicella Zoster Virus (VZV) have been investigated. There is considerable evidence that links EBV with the initiation and progression of MS (Ascherio and Munger, 2007a, b; Dyment et al., 2004). EBV infects over 90% of the world population and causes infectious mononucleosis (IM) in a large proportion of individuals, which is characterized by glandular fever and the massive expansion of virus-specific T cells (Vetsika and Callan, 2004). Pooled data from 18 clinical studies revealed a significant link between IM and an elevated risk of MS (Kakalacheva et al., 2011).
Furthermore, in individuals that concurrently tested positive for IM and the HLA allele
ii. Non-infectious factors
Smoking and Vitamin Dd have been identified as the two primary non-infectious environmental factors that can contribute to MS susceptibility. Although the elevated risk of MS development in individuals who smoke was originally defined identified in a study in the 1960’s (reviewed in (Wingerchuk, 2012)), it has become more prominent in recentl yearsy. Smoking is argued to increase the chance of MS development by a factor of 1.5 (Wingerchuk, 2012). In addition, patients that smoke increase the potential for rapid MS development. In a recent Belgium study, patients that smoked were more likely to develop a score of 6 on the Extended Disability Status Scale. This represents an increased potential to develop intermittent or unilateral constant assistance (cane, crutch or brace) required to walk 100 meters without resting (D'Hooghe M
Vitamin D is a potent immunomodulatory molecule that has been shown to affect numbers and activity of regulatory T cells. Several epidemiological studies have identified a significant link between the incidence of MS and distance from the equator (Kurtzke et al., 1979; Miller et al., 1990; Vukusic et al., 2007). Although MS occurred more frequently at high latitudes, this effect was negated in populations that consumed a vitamin D-rich diet (Agranoff and Goldberg, 1974; Swank et al., 1952; Westlund, 1970). These findings are supported by a large study in which high serum levels of the vitamin D metabolite 25(OH)D were shown to correspond with a significantly decreased risk of MS (Munger et al., 2006). In a separate study, low serum levels of 25(OH)D were associated with relapse and the degree of disability in MS patients (Smolders et al., 2008a).
A possible explanation for these findings is the indirect immunomodulatory functions of vitamin D on T cells (Bartels et al., 2010; Smolders et al., 2008b). Also, T cells express vitamin D receptors (VDR), suggesting a direct vitamin D- T cell interaction resulting in T cell regulation (Cantorna, 2011). Indeed, a recent study using the EAE mouse model demonstrated that vitamin D could inhibit auto-reactive T cells, which express high levels of VDR, but did not affect numbers of regulatory T cells, which express low levels of VDR (Mayne et al., 2011). An earlier study also showed that survival of EAE-induced mice could be prolonged with vitamin D injection (Hayes, 2000).
4. Epitope spreading and disease progression
Multiple sclerosis is initiated by the activation of auto-reactive CD4+ T cells specific for a single or few myelin epitopes in the CNS (Vanderlugt and Miller, 2002). Inflammation caused by this initial response recruits and activates other CD4+ T cell clones specific for a range of other self-epitopes, a process which is referred to as “epitope spreading” (Lehmann et al., 1992). This process occurs, within experimental settings, in a hierarchical fashion, likely the result of differential antigen liberation, processing and presentation by various antigen-presenting cell (APC) populations. In addition the availability of self-reactive CD4+ T cell clones throughout the course of disease is also important. Epitope spreading was originally described and characterized in the Experimental Autoimmune Encephalomyelitis (EAE) model of MS, but also occurs in Theiler’s murine encephalomyelitis virus induced demeylinating disease (TMEV-IDD) (Lehmann et al., 1992; Miller et al., 2001; Miller
1. Epitope spreading in EAE
Experimental autoimmune encephalomyelitis is induced in susceptible murine strains by immunization with myelin peptides in conjunction with adjuvant (Miller et al., 2010). This disease initiation method, with a single and defined myelin peptide allows for the observation and measurement of changing T cell specificities over time (Vanderlugt and Miller, 2002). Using this model epitope spreading has been described as a hierarchical event, with a defined path through which T cells specific for certain epitopes emerge. Epitope spreading is a critical phenomenon in the SJL model of EAE, as it is responsible for the relapsing remitting pattern of disease (Vanderlugt and Miller, 2002).
The first study to demonstrate epitope spreading was reported in 1992 by Lehmann and colleagues (Lehmann
Studies in our laboratory have also characterized epitope spreading in EAE induced by immunization of SJL mice with the immunodominant PLP epitope PLP139-151(Vanderlugt et al., 2000). In this model, T cell responses are initially specific for PLP139-151. However, the first relapse, which occurs within 30-40 days after immunization, coincides with T cell responses against PLP178-191. During the second relapse, which occurs between 50-70 days after immunization, T cells are also shown to respond to MBP84-104. Understanding of the epitope spreading hierarchy has allowed for epitope specific therapeutic targeting in EAE. The induction of tolerance against relapse-associated peptides blocks the progression of disease, even though PLP139-151 responses remain intact (Vanderlugt et al., 2000). These observations highlight the role of changing T cell specificities in mediating chronic disease as well as the need for therapeutic strategies that address these specific T cells populations (Vanderlugt and Miller, 2002).
2. Epitope spreading in TMEV-IDD
Theiler’s murine encephalomyelitis virus- (TMEV)-induced demyelinating disease (TMEV-IDD) is induced by intracranial inoculation of SJL/J mice with TMEV, resulting in low-level chronic CNS infection that progresses into myelin-specific autoimmune disease (Getts et al., 2010).The initial CD4+ T cell-mediated immune response against chronic TMEV infection of the CNS causes significant damage to myelin, which in turn results in the activation of myelin-specific T cell clones (Karpus et al., 1995; Miller et al., 1997a). Similar to EAE, this occurs in a hierarchical order, beginning with the immunodominant PLP139-151 epitope (Miller et al., 1997b). Subsequent T cell reactivity against other peptides, including PLP178-191, PLP56-70 and MOG92-106 has been demonstrated as disease progresses (Miller et al., 2001).
These findings correspond with antigen presentation by CNS APC. These cells present viral peptides but not myelin peptides up to day 40 post-immunization, at which time point there are still no clinical signs of disease and no evidence of myelin destruction (Katz-Levy et al., 1999; Katz-Levy
In further support of epitope spreading after TMEV inoculation, tolerance induction to multiple myelin epitopes using MP-4 during ongoing TMEV-IDD in SJL mice was shown to significantly attenuate disease progression, reduce demyelination and decrease CNS leukocyte infiltration (Neville et al., 2002).
3. Epitope spreading in MS
Evidence of epitope spreading in human MS patients is growing, with a number of small studies at least supporting a potential for epitope spreading in human disease. A study by Tuohy and colleagues conducted over several years followed peripheral T cell responses to myelin epitopes in three patients with isolated monosymptomatic demyelinating syndrome (IMDS) (Tuohy et al., 1997; Tuohy
5. Current clinical strategies in Multiple Sclerosis to modify the course of disease
The pathologic role of T cells in driving MS has resulted in numerous therapies aimed at inactivating T cells and/or the induction of T cell tolerance. Tolerance induction in autoimmune disease refers to a reinstatement of sustained, specific non-responsiveness of the native immune system to self-antigen. Manipulation of T cell activation and differentiation pathways has been at the center of current tolerance induction theory, and the basis of tolerance induction utilizing current immunosuppressive agents. Over recent years, experimental models have shown that it is possible to exploit the mechanisms that normally maintain immune homeostasis and tolerance to self-antigens, as well as to reintroduce tolerance to self-antigen in an autoimmune setting (Getts et al., 2011; Kohm et al., 2005; Podojil et al., 2008; Turley and Miller, 2007). However, in the clinical setting the utilization of co-stimulatory blockade, soluble peptide, altered peptide ligands among others have yielded disappointing results. As such while the induction of tolerance remains the optimal future treatment for MS current therapies are focused on agents that are disease modifying.
Over the last three decades a number of broad acting immune modifying therapeutic options have been developed and introduced to treat MS-patients. None of these therapeutic options is a cure, currently available therapies aim instead to prevent or at least reduce the frequency of relapsing inflammatory events, with the idea of reducing impact of disease on overall quality of life over time (Miller and Rhoades, 2012; Rio et al., 2011). In addition to the clear efficacy requirement long-term safety is also paramount for any MS therapy, with typical MS patients requiring treatment for many decades. The available MS therapies may be divided based on function into “immune modulatory” or “disease modifying” drugs (DMFs) as well as classic immune suppressive substances. In addition, a third group has recently emerged, which includes monoclonal antibodies (biologics). These drugs act by direct interference with specific immune system functions or by broad immune subset depletion. DMFs are typically used early in the course of the disease, whereas immune suppressive drugs and biologics are mostly viewed as treatment options in those patients with abnormally high disease activity, a high risk of sustained disability and/or show poor response to the front line therapeutics (Table 1).
The most widely used disease modifying drugs are Interferon- (IFN) and glatiramer acetate (GLAT) (Johnson, 2012). Both drugs were approved after large phase III studies, which were conducted in the 1990s. These studies proved the efficacy of these drugs in relapsing remitting MS. IFN- and GLAT reduce the relapse rate in relapsing remitting MS patients by up to 50% (Boster et al., 2011; Johnson, 2012; Limmroth et al., 2011). Furthermore, both agents significantly slowed the progression of disease and have an excellent safety profile allowing for long-term utilization. However, there remain a number of administration and efficacy issues with these drugs. Administration is required weekly at a minimum via subcutaneous or intramuscular injection, resulting in significant discomfort to patients. In addition, while IFN- and GLAT have relatively comparable efficacy, there is some patient to patient variability. For example a patient that is not responsive to IFN- may be responsive to GLAT and vicesa versa. Unfortunately no marker exists that may predict those populations that should be prescribed IFN- over GLAT or GLAT over IFN-. Currently trial and error serve as the best strategy for physicians to use when determining the optimal treatment regimen.
The exact mechanism(s) through which GLAT or IFN- modify disease progression in MS patients are not completely defined, with multiple mechanisms likely to be involved. There is evidence suggesting IFN- can inhibit T-cell co-stimulation and activation (Chen et al., 2012). In an experimental setting, IFN- inhibits immune-cell migration by increasing soluble Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1), as well as by decreasing very late antigen-4 (VL4-4) on the cell surface of T cells. It has also been shown that IFN- can stabilize the blood brain barrier by reducing matrix metalloproteinase-9, an important tissue degradation enzyme.
GLAT is a randomized mixture of synthetic polypeptides consisting of the amino acids l-alanine, l-lysine, l-glutamic acid and l-tyrosine. GLAT was originally designed to induce CNS inflammation in animals by stimulating the myelin auto-antigen MBP, however, subsequent studies showed that the product appeared to be a protective immunomodulator. The ability for this drug to prevent relapses and disease progression is supported by large clinical studies. Mechanistically, GLAT may compete with myelin peptides for access to peptide binding cleft in MHC complex (Racke and Lovett-Racke, 2011). In addition to MHC binding, GLAT may stimulate a TH2 environment through its ability to modulate antigen presenting cellsAPC such as dendritic cells and monocytes (Miller et al., 1998). Evidence for the ability of GLAT to induce a TH2 biased immune response includes the finding that GLAT promotes the expression of anti-inflammatory cytokines such as IL-10 and TGF-b in the CNS of MS patients (Neuhaus et al., 2001). More recent studies revealed that GLAT elevates the levels of T-regulatory (Tregs) cells and reduces the levels of potentiallyharmful Th-17 cells (Lalive et al., 2011).
It is difficult to establish the long-term efficacy of drugs in MS because the disease can be highly variable and unpredictable. Still, the available long-term observational data point toward a significant prevention and delay of disability in most MS-pPatients treated with either GLAT or IFN- over a long time. Furthermore, there is sparse evidence that the early treatment reduces the long-term mortality of MS-patients (Goodin et al., 2012).
More recently, new disease-modifying drugs have become or are expected to soon be available (Buck and Hemmer, 2011; Fox and Rhoades, 2012) (Table 1). These drugs include more convenient agents that can be applied orally and may have enhanced efficacy in regards to reducing patient disease activity relative to GLAT or IFN-(Killestein et al., 2011)(Hartung and Aktas, 2011). However, the long-term safety profiles of these substances remains questionable, with more time needed to adequately address the safety profile of these agents.
If front line disease modifying therapies fail to provide sufficient relief, therapeutic escalation to include more effective therapies has to be considered (Repovic and Lublin, 2011). The most effective currently available therapy for escalation is the monoclonal antibody Natalizumab (Tysabri®). Natalizumab acts via the blockade of the VLA-4 receptor, which plays a significant role in leukocyte migration into the brain parenchyma (Rudick and Sandrock, 2004). Clinical studies with Natalizumab have shown this drug to have high efficacy in terms of its ability to prevent disease relapses and progression (Chaudhuri and Behan, 2003; O'Connor
RR-MS, CIS | Flu-like symptoms | good safety profile, inconvenient administr., moderate efficacy (Sanford and Lyseng-Williamson, 2011) | |
RR-MS, CIS | Local irritation, | good safety profile, inconvenient administr., moderate efficacy (Lalive | |
RR-MS or escalation in RR-MS1 | Lymphopenia, arrhythmia, macular edema | Increased relapse reduction compared to IFN-(Singh | |
Escalation in RR-MS | Infections, hepatopathy, allergic response, PML | Excellent efficacy, severe viral encephalitis as a dangerous side-effect (Keegan, 2011; Pucci | |
Escalation in RR-MS, PP-MS, SP-MS, with fast progression | Leukopenia, infections, cardiomyopathy, leukemia | Immunosupressive escalation option. Option in progressive MS courses(Rizvi | |
Escalation in RR-MS, PP-MS, SP-MS, with fast progression | Leukopenia, infections | Therapeutic option if other escalation therapies including mitoxantrone fail(Rinaldi | |
RR-MS? (phase-III trial ongoing) | lymphopenia, hepathopathy | (Warnke | |
RR-MS? (phase-III trial ongoing) | gastrointestinal complaints | (Kappos | |
RR-MS? (phase-III trial ongoing) | Hepatopathy, thrombosis? | (Thone and Gold, 2011) | |
Escalation therapy? (trials ongoing) | Severe infections and sepsis possible, allergic response | (Chaudhuri, 2012; Kappos | |
RR-MS, escalatation? (trials ongoing) | Cutaneous rash, infections | Increased relapse reduction compared to IFN- likely(Stuve and Greenberg, 2010) | |
Escalation therapy? (trials ongoing) | Induction of autoimmune diseases, infections (Cossburn | Increased relapse reduction compared to IFN-(Coles |
The need for safer therapies, combined with animal data showing the ability for short course immune induction therapy (SCIIT) to induce long term disease remission, has supported a new approach to treating MS. SCIIT is a therapeutic strategy employing rapid, specific, short-term modulation of the immune system usually using a biologic therapeutic to induce long term T cell non-responsiveness. Alemtuzumab clinical studies are leading the way in employing this therapeutic concept. In this example, a one week dosing regimen with Alemtuzumab has been in phase 2 and 3 studies shown to have a long term dramatic impact on disease, reducing disease relapses for over a year (Coles
In situations where all other avenues have been exhausted and disease continues to progress at an unusually rapid rate, physicians may prescribe the chemotherapy drugs mitoxantrone or cyclophosphamide (Neuhaus et al., 2006; Perini et al., 2006; Rinaldi et al., 2009; Stuve et al., 2004; Theys et al., 1981). These drugs are often considered as final options due to their potent immunosuppressive and other serious effects. These drugs can suppress both cell-mediated and humoral immunity and often result in lymphopenia, increasing malignancy and infection risk. Results from smaller clinical studies suggest, that treating with these immunosuppressive drugs at the very beginning of the disease and in addition to immune modulating drugs might have a beneficial impact on the course of the disease. However, the harmful side effects associated with thesedrugs means their use is usually restricted to patients that have failed other treatment options, such as Natalizumab.
6. Summary
Multiple Sclerosis (MS) is a chronic, progressive, immune mediated central nervous system disorder that affects both adults and children. The precise triggers of autoreactive T cell development remain to be fully understood, however, it appears that a host of genetic and environmental factors contribute to disease development. Disease initiation may be the result of a single myelin specific T cell clone being activated, however, animal models and preliminary human data suggest that epitope spreading which results in the activation of numerous myelin specific T cells is important for disease progression. Therapies capable of inducing T cell tolerance, thereby rendering these myelin specific T cells inactive remain to be developed for human use. Instead a number of disease modifying agents are available, with GLAT and IFN- being the primary front line MS treatments. In those patients refractory to these therapies or who show a rapid disease progression, escalation to more broad acting therapies, such as Natalizumab may be considered. Unfortunately, while escalating therapies may have enhanced efficacy this comes with increases in safety concerns. In progressive MS patients whereby all other therapies have failed or no longer show efficacy more toxic chemotherapeutic agents are usually the last resort.
Currently within the field of MS treatment, reduction of relapse rates by around 50% is considered to be a success. As such even patients who are considered treatment successes suffer relapses. During these relapses CNS damage and epitope spreading continue to occur with further neurological impairment the result. Future therapies need to have a higher objective and bring the relapse rate down by 75-100%. This goal may not be out of reach with short course Alemtuzumab therapy shown to induce disease remission for an extended period of time. While the safety profile of this drug remains highly questionable, the observed efficacy certainly generates promise that safer more efficacious therapeutic options for MS treatment may soon be available.
References
- 1.
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447 661 678 - 2.
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet41 824 828 - 3.
Agranoff B. W. Goldberg D. 1974 Diet and the geographical distribution of multiple sclerosis. Lancet2 1061 1066 - 4.
BrainAndersen O. (201 Predicting a. window of. therapeutic opportunity. in multiple. sclerosis 133 1863 1865 - 5.
Ascherio A. Munger K. L. 2007a Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol61 288 299 - 6.
Ascherio A. Munger K. L. 2007b Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol61 504 513 - 7.
Baranzini S. E. Wang J. Gibson R. A. Galwey N. Naegelin Y. Barkhof F. Radue E. W. Lindberg R. L. Uitdehaag B. M. Johnson M. R. Angelakopoulou A. Hall L. Richardson J. C. Prinjha R. K. Gass A. Geurts J. J. Kragt J. Sombekke M. Vrenken H. Qualley P. Lincoln R. R. Gomez R. Caillier S. J. George M. F. Mousavi H. Guerrero R. Okuda D. T. Cree B. A. Green A. J. Waubant E. Goodin D. S. Pelletier D. Matthews P. M. Hauser S. L. Kappos L. Polman C. H. Oksenberg J. R. 2009 Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet18 767 778 - 8.
Bartels L. E. Hvas C. L. Agnholt J. Dahlerup J. F. Agger R. 2010 Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int Immunopharmacol10 922 928 - 9.
Berger J. R. Koralnik I. J. 2005 Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med353 414 416 - 10.
Boster A. Bartoszek M. P. O’Connell C. Pitt D. Racke M. 2011 Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord4 319 332 - 11.
Bradl M. Lassmann H. 2009 Progressive multiple sclerosis. Semin Immunopathol. - 12.
Bronner G. Elran E. Golomb J. Korczyn A. D. 2010 Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. Acta Neurol Scand121 289 301 - 13.
Bruck W. 2005 The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 252 Suppl 5,3-9 - 14.
Bruck W. Stadelmann C. 2005 The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol18 221 224 - 15.
Brynedal B. Duvefelt K. Jonasdottir G. Roos I. M. Akesson E. Palmgren J. Hillert J. 2007 HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2, e664. - 16.
Buck D. Hemmer B. 2011 Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol258 1747 1762 - 17.
Cantorna M. T. 2011 Why do T cells express the vitamin D receptor? Ann N Y Acad Sci1217 77 82 - 18.
Chaudhuri A. 2012 Ocrelizumab in multiple sclerosis: risks and benefits. Lancet379 1196 1197 author reply 1197. - 19.
Chaudhuri A. Behan P. O. 2003 Natalizumab for relapsing multiple sclerosis. N Engl J Med348 1598 1599 author reply 1598-1599. - 20.
Chen M. Chen G. Deng S. Liu X. Hutton G. J. Hong J. 2012 IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol242 39 46 - 21.
Chitnis T. Glanz B. Jaffin S. Healy B. 2009 Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler15 627 631 - 22.
interferon beta-1a in early multiple sclerosis. N Engl J MedColes A. J. Compston D. A. Selmaj K. W. Lake S. L. Moran S. Margolin D. H. Norris K. Tandon P. K. (200 vs Alemtuzumab 359 1786 1801 - 23.
Coles A. J. Fox E. Vladic A. Gazda S. K. Brinar V. Selmaj K. W. Skoromets A. Stolyarov I. Bass A. Sullivan H. Margolin D. H. Lake S. L. Moran S. Palmer J. Smith M. S. Compston D. A. 2012 Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology78 1069 1078 - 24.
Cossburn M. Pace A. A. Jones J. Ali R. Ingram G. Baker K. Hirst C. Zajicek J. Scolding N. Boggild M. Pickersgill T. Ben-Shlomo Y. Coles A. Robertson N. P. 2011 Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology77 573 579 - 25.
D’Hooghe M. B. Haentjens P. Nagels G. De Keyser J. 2012 Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol19 616 624 - 26.
Dyment D. A. Ebers G. C. Sadovnick A. D. 2004 Genetics of multiple sclerosis. Lancet Neurol3 104 110 - 27.
Hum Mol GenetDyment D. A. Herrera B. M. Cader M. Z. Willer C. J. Lincoln M. R. Sadovnick A. D. Risch N. Ebers G. C. (200 Complex interactions. among M. H. C. haplotypes in. multiple sclerosis. susceptibility resistance 14 2019 2026 - 28.
Ebers G. C. Sadovnick A. D. Dyment D. A. Yee I. M. Willer C. J. Risch N. 2004 Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet363 1773 1774 - 29.
Ebers G. C. Yee I. M. Sadovnick A. D. Duquette P. 2000 Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol48 927 931 - 30.
Fogdell A. Hillert J. Sachs C. Olerup O. 1995 The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens46 333 336 - 31.
Fox E. J. Rhoades R. W. 2012 New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 25 Suppl, S11 19 - 32.
J., Luo, X., Terry, R. L., King, N. J. and Miller, S. D. (Getts D. R. Turley D. M. Smith C. E. Harp C. T. Mc Carthy D. Feeney E. M. Getts M. T. Martin A. J. Luo X. Terry R. L. King N. J. Miller S. D. (201 Tolerance induced. by apoptotic. antigen-coupled leukocytes. is induced. by-L P. D. L-10-producing I. splenic macrophages. maintained by. T. regulatory cells. 2011 Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol187 2405 2417 - 33.
Getts M. T. Richards M. H. Miller S. D. 2010 A critical role for virus-specific CD8(+) CTLs in protection from Theiler’s virus-induced demyelination in disease-susceptible SJL mice. Virology402 102 111 - 34.
Goebels N. Hofstetter H. Schmidt S. Brunner C. Wekerle H. Hohlfeld R. 2000 Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123 Pt3 508 518 - 35.
and Year Long Term Follow-up Study, I. (Goodin D. S. Traboulsee A. Knappertz V. Reder A. T. Li D. Langdon D. Wolf C. Beckmann K. Konieczny A. Ebers G. 2012 Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry83 282 287 - 36.
Goverman J. 2009 Autoimmune T cell responses in the central nervous system. Nat Rev Immunol9 393 407 - 37.
Grau-Lopez L. Raich D. Ramo-Tello C. Naranjo-Gomez M. Davalos A. Pujol-Borrell R. Borras F. E. Martinez-Caceres E. 2009 Myelin peptides in multiple sclerosis. Autoimmun Rev8 650 653 - 38.
Hafler D. A. 2004 Multiple sclerosis. J Clin Invest113 788 794 - 39.
Hafler D. A. Compston A. Sawcer S. Lander E. S. Daly M. J. De Jager P. L. de Bakker P. I. Gabriel S. B. Mirel D. B. Ivinson A. J. Pericak-Vance M. A. Gregory S. G. Rioux J. D. Mc Cauley J. L. Haines J. L. Barcellos L. F. Cree B. Oksenberg J. R. Hauser S. L. 2007 Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med357 851 862 - 40.
Hansen T. Skytthe A. Stenager E. Petersen H. C. Bronnum-Hansen H. Kyvik K. O. 2005 Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler11 504 510 - 41.
Hartung H. P. Aktas O. 2011 Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol10 293 295 - 42.
N Engl J MedHauser S. L. (200 Multiple lessons. for multiple. sclerosis 359 1838 1841 - 43.
Hayes C. E. 2000 Vitamin D: a natural inhibitor of multiple sclerosis. Proc Nutr Soc59 531 535 - 44.
Mol Cell ProbesHoffjan S. Akkad D. A. (201 The genetics. of multiple. sclerosis an. update 201. 24 237 243 - 45.
Holland N. J. 2009 Overview of Multiple Sclerosis. Clinical Bulletin, Information for health professionals. National Multiple Sclerosis Soceity. - 46.
Biochim Biophys ActaHoppenbrouwers I. A. Hintzen R. Q. (201 Genetics of. multiple sclerosis. 1812 194 201 - 47.
Islam T. Gauderman W. J. Cozen W. Hamilton A. S. Burnett M. E. Mack T. M. 2006 Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann Neurol60 56 64 - 48.
Jeffery D. R. Markowitz C. E. Reder A. T. Weinstock-Guttman B. Tobias K. 2011 Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother11 165 183 - 49.
Jersild C. Fog T. Hansen G. S. Thomsen M. Svejgaard A. Dupont B. 1973 Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet2 1221 1225 - 50.
Jersild C. Svejgaard A. Fog T. 1972 HL-A antigens and multiple sclerosis. Lancet1 1240 1241 - 51.
Johnson K. P. 2012 Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother12 371 384 - 52.
Kakalacheva K. Lunemann J. D. 2011 Environmental triggers of multiple sclerosis. FEBS Lett585 3724 3729 - 53.
Biochim Biophys ActaKakalacheva K. Munz C. Lunemann J. D. (201 Viral triggers. of multiple. sclerosis 1812 132 140 - 54.
Kappos L. Bates D. Edan G. Eraksoy M. Garcia-Merino A. Grigoriadis N. Hartung H. P. Havrdova E. Hillert J. Hohlfeld R. Kremenchutzky M. Lyon-Caen O. Miller A. Pozzilli C. Ravnborg M. Saida T. Sindic C. Vass K. Clifford D. B. Hauser S. Major E. O. O’Connor P. W. Weiner H. L. Clanet M. Gold R. Hirsch H. H. Radu E. W. Sorensen P. S. King J. 2011a Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol10 745 758 - 55.
Kappos L. Gold R. Miller D. H. Macmanus D. G. Havrdova E. Limmroth V. Polman C. H. Schmierer K. Yousry T. A. Yang M. Eraksoy M. Meluzinova E. Rektor I. Dawson K. T. Sandrock A. W. O’Neill G. N. Investigators B. G. P. I. S. 2008 Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet372 1463 1472 - 56.
Kappos L. Li D. Calabresi P. A. O’Connor P. Bar-Or A. Barkhof F. Yin M. Leppert D. Glanzman R. Tinbergen J. Hauser S. L. 2011b Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet378 1779 1787 - 57.
Karpus W. J. Pope J. G. Peterson J. D. Dal Canto. M. C. Miller S. D. 1995 Inhibition of Theiler’s virus-mediated demyelination by peripheral immune tolerance induction. J Immunol155 947 957 - 58.
Katz-Levy Y. Neville K. L. Girvin A. M. Vanderlugt C. L. Pope J. G. Tan L. J. Miller S. D. 1999 Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler’s virus-infected mice. J Clin Invest104 599 610 - 59.
Katz-Levy Y. Neville K. L. Padilla J. Rahbe S. Begolka W. S. Girvin A. M. Olson J. K. Vanderlugt C. L. Miller S. D. 2000 Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler’s virus-infected mice. J Immunol165 5304 5314 - 60.
Keegan B. M. 2011 Natalizumab for multiple sclerosis: a complicated treatment. Lancet Neurol10 677 678 - 61.
Killestein J. Rudick R. A. Polman C. H. 2011 Oral treatment for multiple sclerosis. Lancet Neurol10 1026 1034 - 62.
Klotz L. Meuth S. G. Wiendl H. 2012 Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol142 25 30 - 63.
Kohm A. P. Turley D. M. Miller S. D. 2005 Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease. Int Rev Immunol24 361 392 - 64.
Kurtzke J. F. Beebe G. W. Norman J. E. Jr 1979 Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology29 1228 1235 - 65.
Lalive P. H. Neuhaus O. Benkhoucha M. Burger D. Hohlfeld R. Zamvil S. S. Weber M. S. 2011 Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs25 401 414 - 66.
Lang H. L. Jacobsen H. Ikemizu S. Andersson C. Harlos K. Madsen L. Hjorth P. Sondergaard L. Svejgaard A. Wucherpfennig K. Stuart D. I. Bell J. I. Jones E. Y. Fugger L. 2002 A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol3 940 943 - 67.
Langer-Gould A. Atlas S. W. Green A. J. Bollen A. W. Pelletier D. 2005 Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med353 375 381 - 68.
Lehmann P. V. Forsthuber T. Miller A. Sercarz E. E. 1992 Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature358 155 157 - 69.
Limmroth V. Putzki N. Kachuck N. J. 2011 The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord4 281 296 - 70.
Lincoln M. R. Montpetit A. Cader M. Z. Saarela J. Dyment D. A. Tiislar M. Ferretti V. Tienari P. J. Sadovnick A. D. Peltonen L. Ebers G. C. Hudson T. J. 2005 A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet37 1108 1112 - 71.
Mah J. K. Thannhauser J. E. 2010 Management of multiple sclerosis in adolescents- current treatment options related adherence issues. Adolescent Health, Medicine and Therapeutics1 31 43 - 72.
Mayne C. G. Spanier J. A. Relland L. M. Williams C. B. Hayes C. E. 2011 Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur J Immunol41 822 832 - 73.
Miller A. Shapiro S. Gershtein R. Kinarty A. Rawashdeh H. Honigman S. Lahat N. 1998 Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol92 113 121 - 74.
Miller A. E. Rhoades R. W. 2012 Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr Opin Neurol 25 Suppl, S4 10 - 75.
Miller D. H. Hammond S. R. Mc Leod J. G. Purdie G. Skegg D. C. 1990 Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry53 903 905 - 76.
Miller S. D. Eagar T. N. 2001 Functional role of epitope spreading in the chronic pathogenesis of autoimmune and virus-induced demyelinating diseases. Adv Exp Med Biol490 99 107 - 77.
Miller S. D. Karpus W. J. Davidson T. S. 2010 Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol Chapter 15, Unit 15 11. - 78.
Miller S. D. Katz-Levy Y. Neville K. L. Vanderlugt C. L. 2001 Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler’s virus infection of the central nervous system. Adv Virus Res56 199 217 - 79.
Miller S. D. Vanderlugt C. L. Begolka W. S. Pao W. Neville K. L. Yauch R. L. Kim B. S. 1997a Epitope spreading leads to myelin-specific autoimmune responses in SJL mice chronically infected with Theiler’s virus. J Neurovirol 3 Suppl 1, S62 65 - 80.
Miller S. D. Vanderlugt C. L. Begolka W. S. Pao W. Yauch R. L. Neville K. L. Katz-Levy Y. Carrizosa A. Kim B. S. 1997b Persistent infection with Theiler’s virus leads to CNS autoimmunity via epitope spreading. Nat Med3 1133 1136 - 81.
Modin H. Olsson W. Hillert J. Masterman T. 2004 Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. Am J Hum Genet74 1321 1322 - 82.
Moreau T. Coles A. Wing M. Thorpe J. Miller D. Moseley I. Issacs J. Hale G. Clayton D. Scolding N. Waldmann H. Compston A. 1996 CAMPATH-IH in multiple sclerosis. Mult Scler1 357 365 - 83.
Munger K. L. Levin L. I. Hollis B. W. Howard N. S. Ascherio A. 2006 Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA296 2832 2838 - 84.
Naito S. Namerow N. Mickey M. R. Terasaki P. I. 1972 Multiple sclerosis: association with HL-A3. Tissue Antigens2 1 4 - 85.
Neuhaus O. Farina C. Wekerle H. Hohlfeld R. 2001 Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology56 702 708 - 86.
Neuhaus O. Kieseier B. C. Hartung H. P. 2006 Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther109 198 209 - 87.
Neville K. L. Padilla J. Miller S. D. 2002 Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS. J Neuroimmunol123 18 29 - 88.
Nischwitz S. Muller-Myhsok B. Weber F. 2011 Risk conferring genes in multiple sclerosis. FEBS Lett585 3789 3797 - 89.
NeurologyO’Connor P. W. Goodman A. Kappos L. Lublin F. D. Miller D. H. Polman C. Rudick R. A. Aschenbach W. Lucas N. (201 Disease activity. return during. natalizumab treatment. interruption in. patients with. multiple sclerosis. 76 1858 1865 - 90.
and Natalizumab Multiple Sclerosis Trial, G. (O’Connor P. W. Goodman A. Willmer-Hulme A. J. Libonati M. A. Metz L. Murray R. S. Sheremata W. A. Vollmer T. L. Stone L. 2004 Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology62 2038 2043 - 91.
Oksenberg J. R. Barcellos L. F. Cree B. A. Baranzini S. E. Bugawan T. L. Khan O. Lincoln R. R. Swerdlin A. Mignot E. Lin L. Goodin D. Erlich H. A. Schmidt S. Thomson G. Reich D. E. Pericak-Vance M. A. Haines J. L. Hauser S. L. 2004 Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet74 160 167 - 92.
Olson J. K. Croxford J. L. Calenoff M. A. Dal Canto. M. C. Miller S. D. 2001 A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest108 311 318 - 93.
Papadopoulou A. D’Souza M. Kappos L. Yaldizli O. 2010 Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs19 1603 1612 - 94.
Perini P. Calabrese M. Tiberio M. Ranzato F. Battistin L. Gallo P. 2006 Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol253 1034 1040 - 95.
Podojil J. R. Turley D. M. Miller S. D. 2008 Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease. Adv Exp Med Biol640 234 251 - 96.
Pohl D. Waubant E. Banwell B. Chabas D. Chitnis T. Weinstock-Guttman B. Tenembaum S. 2007 Treatment of pediatric multiple sclerosis and variants. Neurology 68, S54 65 - 97.
Pravica V. Popadic D. Savic E. Markovic M. Drulovic J. Mostarica-Stojkovic M. 2012 Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers. Immunol Res. - 98.
Pucci E. Giuliani G. Solari A. Simi S. Minozzi S. Di Pietrantonj C. Galea I. 2011 Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev, CD007621. - 99.
J ImmunolRacke M. K. Lovett-Racke A. E. (201 Glatiramer acetate. treatment of. multiple sclerosis. an immunological. perspective 186 1887 1890 - 100.
Ramagopalan S. V. Knight J. C. Ebers G. C. 2009 Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol22 219 225 - 101.
Ramagopalan S. V. Morris A. P. Dyment D. A. Herrera B. M. De Luca G. C. Lincoln M. R. Orton S. M. Chao M. J. Sadovnick A. D. Ebers G. C. 2007 The inheritance of resistance alleles in multiple sclerosis. PLoS Genet3 1607 1613 - 102.
Ransohoff R. M. 2005 Natalizumab and PML. Nat Neurosci 8, 1275. - 103.
Repovic P. Lublin F. D. 2011 Treatment of multiple sclerosis exacerbations. Neurol Clin29 389 400 - 104.
Rinaldi L. Perini P. Calabrese M. Gallo P. 2009 Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol Sci 30 Suppl 2, S171 173 - 105.
Rio J. Comabella M. Montalban X. 2011 Multiple sclerosis: current treatment algorithms. Curr Opin Neurol24 230 237 - 106.
Rizvi S. A. Zwibel H. Fox E. J. 2004 Mitoxantrone for multiple sclerosis in clinical practice. Neurology 63, S25 27 - 107.
Robertson N. P. O’Riordan J. I. Chataway J. Kingsley D. P. Miller D. H. Clayton D. Compston D. A. 1997 Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet349 1587 1590 - 108.
Rudick R. A. Sandrock A. 2004 Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother4 571 580 - 109.
DrugsSanford M. Lyseng-Williamson K. A. (201 Subcutaneous recombinant. interferon-beta-1a . Rebif R). review a. of its. use in. the treatment. of relapsing. multiple sclerosis. 71 1865 1891 - 110.
Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C. C., Patsopoulos, N. A., Moutsianas, L., Dilthey, A., Su, Z., Freeman, C., Hunt, S. E., Edkins, S., Gray, E., Booth, D. R., Potter, S. C., Goris, A., Band, G., Oturai, A. B., Strange, A., Saarela, J., Bellenguez, C., Fontaine, B., Gillman, M., Hemmer, B., Gwilliam, R., Zipp, F., Jayakumar, A., Martin, R., Leslie, S., Hawkins, S., Giannoulatou, E., D’Alfonso, S., Blackburn, H., Martinelli Boneschi, F., Liddle, J., Harbo, H. F., Perez, M. L., Spurkland, A., Waller, M. J., Mycko, M. P., Ricketts, M., Comabella, M., Hammond, N., Kockum, I., McCann, O. T., Ban, M., Whittaker, P., Kemppinen, A., Weston, P., Hawkins, C., Widaa, S., Zajicek, J., Dronov, S., Robertson, N., Bumpstead, S. J., Barcellos, L. F., Ravindrarajah, R., Abraham, R., Alfredsson, L., Ardlie, K., Aubin, C., Baker, A., Baker, K., Baranzini, S. E., Bergamaschi, L., Bergamaschi, R., Bernstein, A., Berthele, A., Boggild, M., Bradfield, J. P., Brassat, D., Broadley, S. A., Buck, D., Butzkueven, H., Capra, R., Carroll, W. M., Cavalla, P., Celius, E. G., Cepok, S., Chiavacci, R., Clerget-Darpoux, F., Clysters, K., Comi, G., Cossburn, M., Cournu-Rebeix, I., Cox, M. B., Cozen, W., Cree, B. A., Cross, A. H., Cusi, D., Daly, M. J., Davis, E., de Bakker, P. I., Debouverie, M., D’Hooghe M, B., Dixon, K., Dobosi, R., Dubois, B., Ellinghaus, D., Elovaara, I., Esposito, F., Fontenille, C., Foote, S., Franke, A., Galimberti, D., Ghezzi, A., Glessner, J., Gomez, R., Gout, O., Graham, C., Grant, S. F., Guerini, F. R., Hakonarson, H., Hall, P., Hamsten, A., Hartung, H. P., Heard, R. N., Heath, S., Hobart, J., Hoshi, M., Infante-Duarte, C., Ingram, G., Ingram, W., Islam, T., Jagodic, M., Kabesch, M., Kermode, A. G., Kilpatrick, T. J., Kim, C., Klopp, N., Koivisto, K., Larsson, M., Lathrop, M., Lechner-Scott, J. S., Leone, M. A., Leppa, V., Liljedahl, U., Bomfim, I. L., Lincoln, R. R., Link, J., Liu, J., Lorentzen, A. R., Lupoli, S., Macciardi, F., Mack, T., Marriott, M., Martinelli, V., Mason, D., McCauley, J. L., Mentch, F., Mero, I. L., Mihalova, T., Montalban, X., Mottershead, J., Myhr, K. M., Naldi, P., Ollier, W., Page, A., Palotie, A., Pelletier, J., Piccio, L., Pickersgill, T., Piehl, F., Pobywajlo, S., Quach, H. L., Ramsay, P. P., Reunanen, M., Reynolds, R., Rioux, J. D., Rodegher, M., Roesner, S., Rubio, J. P., Ruckert, I. M., Salvetti, M., Salvi, E., Santaniello, A., Schaefer, C. A., Schreiber, S., Schulze, C., Scott, R. J., Sellebjerg, F., Selmaj, K. W., Sexton, D., Shen, L., Simms-Acuna, B., Skidmore, S., Sleiman, P. M., Smestad, C., Sorensen, P. S., Sondergaard, H. B., Stankovich, J., Strange, R. C., Sulonen, A. M., Sundqvist, E., Syvanen, A. C., Taddeo, F., Taylor, B., Blackwell, J. M., Tienari, P., Bramon, E., Tourbah, A., Brown, M. A., Tronczynska, E., Casas, J. P., Tubridy, N., Corvin, A., Vickery, J., Jankowski, J., Villoslada, P., Markus, H. S., Wang, K., Mathew, C. G., Wason, J., Palmer, C. N., Wichmann, H. E., Plomin, R., Willoughby, E., Rautanen, A., Winkelmann, J., Wittig, M., Trembath, R. C., Yaouanq, J., Viswanathan, A. C., Zhang, H., Wood, N. W., Zuvich, R., Deloukas, P., Langford, C., Duncanson, A., Oksenberg, J. R., Pericak-Vance, M. A., Haines, J. L., Olsson, T., Hillert, J., Ivinson, A. J., De Jager, P. L., Peltonen, L., Stewart, G. J., Hafler, D. A., Hauser, S. L., McVean, G., Donnelly, P. and Compston, A. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219. - 111.
Singh M. Cugati G. Singh P. Singh A. K. 2011 Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis. J Pharm Bioallied Sci3 460 461 - 112.
Smolders J. Damoiseaux J. Menheere P. Hupperts R. 2008a Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol194 7 17 - 113.
Smolders J. Menheere P. Kessels A. Damoiseaux J. Hupperts R. 2008b Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler14 1220 1224 - 114.
Stuve O. Greenberg B. M. 2010 Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. Lancet Neurol9 337 338 - 115.
Stuve O. Kita M. Pelletier D. Fox R. J. Stone J. Goodkin D. E. Zamvil S. S. 2004 Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 10 Suppl 1, S58 61 - 116.
Swank R. L. Lerstad O. Strom A. Backer J. 1952 Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med246 722 728 - 117.
Terasaki P. I. Park M. S. Opelz G. Ting A. 1976 Multiple sclerosis and high incidence of a B lymphocyte antigen. Science193 1245 1247 - 118.
Theys P. Gosseye-Lissoir F. Ketelaer P. Carton H. 1981 Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study. J Neurol225 119 133 - 119.
Thone J. Gold R. 2011 Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol7 365 370 - 120.
Tuohy V. K. Yu M. Weinstock-Guttman B. Kinkel R. P. 1997 Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest99 1682 1690 - 121.
Tuohy V. K. Yu M. Yin L. Kawczak J. A. Kinkel P. R. 1999a Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun13 11 20 - 122.
Tuohy V. K. Yu M. Yin L. Kawczak J. A. Kinkel R. P. 1999b Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med189 1033 1042 - 123.
J ImmunolTurley D. M. Miller S. D. (200 Peripheral tolerance. induction using. ethylenecarbodiimide-fixed A. P. Cs uses. both direct. indirect mechanisms. of antigen. presentation for. prevention of. experimental autoimmune. encephalomyelitis 178 2212 2220 - 124.
Vanderlugt C. L. Miller S. D. 2002 Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol2 85 95 - 125.
Vanderlugt C. L. Neville K. L. Nikcevich K. M. Eagar T. N. Bluestone J. A. Miller S. D. 2000 Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol164 670 678 - 126.
Vetsika E. K. Callan M. 2004 Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med6 1 16 - 127.
Vukusic S. Van Bockstael V. Gosselin S. Confavreux C. 2007 Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry78 707 709 - 128.
Warnke C. Meyer zu. Horste G. Hartung H. P. Stuve O. Kieseier B. C. 2009 Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat5 333 340 - 129.
Weiner H. L. Hauser S. L. Hafler D. A. Fallis R. J. Lehrich J. R. Dawson D. M. 1984 The use of cyclophosphamide in the treatment of multiple sclerosis. Ann N Y Acad Sci436 373 381 - 130.
Westlund K. 1970 Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand46 455 483 - 131.
Willer C. J. Dyment D. A. Risch N. J. Sadovnick A. D. Ebers G. C. 2003 Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A100 12877 12882 - 132.
Winchester R. Ebers G. Fu S. M. Espinosa L. Zabriskie J. Kunkel H. G. 1975 B-cell alloantigen Ag 7a in multiple sclerosis. Lancet 2, 814. - 133.
Wingerchuk D. M. 2012 Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord5 13 22 - 134.
Wood H. 2011 Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial. Nat Rev Neurol 7, 657. - 135.
Wynn D. Kaufman M. Montalban X. Vollmer T. Simon J. Elkins J. O’Neill G. Neyer L. Sheridan J. Wang C. Fong A. Rose J. W. investigators C. 2010 Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol9 381 390